{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:56:59Z","timestamp":1780451819693,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ijcard.2023.131613","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T11:33:25Z","timestamp":1701084805000},"page":"131613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The real-world safety of sacubitril \/ valsartan among older adults (\u226575): A pharmacovigilance study from the FDA data"],"prefix":"10.1016","volume":"397","author":[{"given":"Tsahi T.","family":"Lerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeela","family":"Talmor-Barkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menachem","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idan","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Kornowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2023.131613_bb0005","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ejhf.548","article-title":"Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens","volume":"18","author":"Senni","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2023.131613_bb0010","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/FJC.0000000000000641","article-title":"Sacubitril\/valsartan in daily clinical practice: data from a prospective registry","volume":"73","author":"Vicent","year":"2019","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2023.131613_bb0015","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.ijcard.2023.131613_bb0020","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021459","article-title":"Clinical Effectiveness of Sacubitril\/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction","volume":"10","author":"Greene","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"2021","key":"10.1016\/j.ijcard.2023.131613_bb0025","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2023.131613_bb0030","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2023.131613_bb0035","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.ijcard.2023.131613_bb0040","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s11897-014-0220-x","article-title":"Understanding the epidemic of heart failure: past, present, and future","volume":"11","author":"Dunlay","year":"2014","journal-title":"Curr. Heart Fail. Rep."},{"key":"10.1016\/j.ijcard.2023.131613_bb0045","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa1406656","article-title":"Demographic and epidemiologic drivers of global cardiovascular mortality","volume":"372","author":"Roth","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2023.131613_bb0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card. Fail. Rev."},{"key":"10.1016\/j.ijcard.2023.131613_bb0055","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijcard.2021.01.061","article-title":"Real-world effectiveness and safety of sacubitril\/valsartan in heart failure: a systematic review","volume":"331","author":"Proudfoot","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131613_bb0060","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijcard.2019.05.048","article-title":"Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: a meta-analysis of randomized controlled trials","volume":"293","author":"Geng","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131613_bb0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12933-023-01743-5","article-title":"The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (\u2265 75 years): a retrospective, pharmacovigilance study","volume":"22","author":"Goldman","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ijcard.2023.131613_bb0070","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","article-title":"Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF","volume":"36","author":"Jhund","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2023.131613_bb0075","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","article-title":"Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension","volume":"69","author":"Williams","year":"2017","journal-title":"Hypertension."},{"key":"10.1016\/j.ijcard.2023.131613_bb0080","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jchf.2022.07.001","article-title":"Age differences in effects of Sacubitril\/valsartan on cardiac remodeling, biomarkers, and health status","volume":"10","author":"Murphy","year":"2022","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ijcard.2023.131613_bb0085","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/ajh\/hpx111","article-title":"Efficacy and safety of sacubitril\/valsartan (LCZ696) compared with olmesartan in elderly asian patients (\u226565 years) with systolic hypertension","volume":"30","author":"Supasyndh","year":"2017","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2023.131613_bb0090","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1111\/bcp.14868","article-title":"Pharmacovigilance-based drug repurposing: the search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections","volume":"87","author":"B\u00f6hm","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2023.131613_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2023.131613_bb0100","doi-asserted-by":"crossref","DOI":"10.1186\/s40360-020-00447-w","article-title":"Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system","volume":"21","author":"Huang","year":"2020","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.ijcard.2023.131613_bb0105","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1038\/s41598-023-27687-0","article-title":"Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA adverse event reporting system database","volume":"13","author":"Li","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijcard.2023.131613_bb0110","doi-asserted-by":"crossref","first-page":"1045561","DOI":"10.3389\/fphar.2022.1045561","article-title":"Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: a real-world analysis using the FDA adverse event reporting system","volume":"13","author":"Jiao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijcard.2023.131613_bb0115","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ane.13690","article-title":"Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: a disproportionality analysis","volume":"146","author":"Sharma","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.ijcard.2023.131613_bb0120","first-page":"1","article-title":"Safety profile of clobazam in the real world: an analysis of FAERS database and systematic review of case reports","author":"An","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ijcard.2023.131613_bb0125","article-title":"Identification of signal of clindamycin associated renal failure acute: a disproportionality analysis","author":"Javed","year":"2023","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.ijcard.2023.131613_bb0130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Statistics notes: interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ."},{"key":"10.1016\/j.ijcard.2023.131613_bb0135","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/sj.ki.5001648","article-title":"Late-onset renal failure from RAAS blockade","volume":"70","author":"Onuigbo","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.ijcard.2023.131613_bb0140","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin. Pract."},{"key":"10.1016\/j.ijcard.2023.131613_bb0145","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cardfail.2022.09.004","article-title":"Risk of acute kidney injury among older adults with heart failure and with reduced ejection fraction treated with angiotensin-neprilysin inhibitor vs renin-angiotensin system inhibitor in routine clinical care","volume":"29","author":"Bhatt","year":"2023","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ijcard.2023.131613_bb0150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2023.131613_bb0155","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijcard.2020.08.067","article-title":"Angioedema with sacubitril\/valsartan: trial-level meta-analysis of over 14,000 patients and real-world evidence to date","volume":"323","author":"Dani","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131613_bb0160","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijcard.2018.03.121","article-title":"Angioedema in heart failure patients treated with sacubitril\/valsartan (LCZ696) or enalapril in the PARADIGM-HF study","volume":"264","author":"Shi","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131613_bb0165","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2022.10.033","article-title":"Comparative risk of angioedema with sacubitril-valsartan vs renin-angiotensin-aldosterone inhibitors","volume":"81","author":"Eworuke","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131613_bb0170","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.numecd.2018.02.014","article-title":"Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems","volume":"28","author":"Raschi","year":"2018","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.ijcard.2023.131613_bb0175","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.2147\/DDDT.S81998","article-title":"Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases","volume":"9","author":"Nomura","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ijcard.2023.131613_bb0180","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijcard.2021.09.013","article-title":"Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: observations from the Swedish heart failure registry","volume":"343","author":"Kapelios","year":"2021","journal-title":"Int. J. Cardiol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527323017035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527323017035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:04:35Z","timestamp":1759093475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527323017035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":36,"alternative-id":["S0167527323017035"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2023.131613","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The real-world safety of sacubitril \/ valsartan among older adults (\u226575): A pharmacovigilance study from the FDA data","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2023.131613","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"131613"}}